Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca today announced the first patient was dosed in DESTINYLung02, a global phase 2 trial evaluating the safety and efficacy of ENHERTU® (trastuzumab deruxtecan) in patients with HER2 mutated metastatic non-small cell lung cancer (NSCLC) with disease recurrence or progression during or after at least one prior platinum-containing treatment regimen.
Lung cancer is the leading cause of cancer death among both men and women, and accounts for about one fifth of all cancer deaths globally, with 80 to 85% classified as NSCLC.1,2,3 For patients with metastatic disease, prognosis is particularly poor, as only approximately 6% live beyond five years after diagnosis.4 There are currently no medicines approved specifically for the treatment of HER2 mutated NSCLC, which affects approximately 2 to 4% of patients with NSCLC.5,6
“Identification of the HER2 mutation as a distinct molecular target in non-small cell lung cancer has opened up a new and exciting area of research. Our initial research of ENHERTU in the DESTINY-Lung01 trial has shown impressive early results in patients with HER2 mutated metastatic non-small cell lung cancer,” said Gilles Gallant, BPharm, PhD, FOPQ, Senior Vice President, Global Head, Oncology Development, Oncology R&D, Daiichi Sankyo. “Building on these results, we are initiating the DESTINY-Lung02 trial to further explore the safety and efficacy of two different doses of ENHERTU in this specific type of non-small cell lung cancer.”
1 World Health Organization. International Agency for Research on Cancer. Lung Fact Sheet. Accessed February 2021.
2 ASCO. Cancer.net. Lung Cancer – Non-Small Cell. Accessed February 2021.
3 Cheema PK, et al. Curr Oncol. 2019;26(1):37-42.
4 ASCO. Cancer.net. Lung Cancer – Non-Small Cell: Statistics. Accessed March 2021.
5 Liu S et al. Clin Cancer Res. 2018;24(11):2594-2604.
6 Campbell JD, et al. Nat Genet. 2016 Jun;48(6):607-16.